clinical trial · NCT05415410
Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)
VectivBio AG·phase2·terminated·n = 31
GVHDApraglutide
brief summary
The aim of this trial is to assess safety and efficacy of apraglutide in subjects with steroid refractory gastrointestinal aGVHD.
started
May 25, 2022
primary completion
Dec 17, 2024
completion
Dec 17, 2024
last updated
Oct 20, 2025
detailed description
This is an international, multicenter, randomized proof-of-concept trial to evaluate safety, tolerability, efficacy, durability of response, and clinical outcomes of apraglutide administration to subjects with steroid-refractory (SR) aGVHD of the lower GI tract being treated with systemic steroids (SS) and ruxolitinib (RUX).
official title
A Randomized, Single-blind Trial to Evaluate the Safety and Efficacy of Apraglutide in Subjects With Grade II to IV (MAGIC) Steroid Refractory Gastrointestinal (GI) Acute Graft Versus Host Disease on Best Available Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol